Volume 27, Issue 2 pp. 83-88
Therapeutic Hotline

Is the step-up therapy of topical 5-aminolevulinic acid photodynamic therapy effective and safe for the patients with recalcitrant facial flat wart?

Ge Qian

Ge Qian

Department of Dermatology and Venereology, The 2nd Affiliated Hospital of Kunming Medical University, Kunming, China

Search for more papers by this author
Sisi Wang

Sisi Wang

Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou, China

Search for more papers by this author
Danqi Deng

Danqi Deng

Department of Dermatology and Venereology, The 2nd Affiliated Hospital of Kunming Medical University, Kunming, China

Search for more papers by this author
Gaoyun Yang

Corresponding Author

Gaoyun Yang

Department of Dermatology and Venereology, Beijing Friendship Hospital, Capital Medical University, Beijing, China

Address correspondence and reprint requests to: Gaoyun Yang, MD, PhD, Department of Dermatology and Venereology, Beijing Friendship Hospital, Capital Medical University, No. 95 Yongan Road, Xicheng District, Beijing 100050, China, or email: [email protected].Search for more papers by this author
First published: 20 May 2013
Citations: 13
Funding sources: None.
Conflict of interest disclosure: None declared.

Abstract

Facial flat wart, caused by human papilloma virus type 3 and less often, type 10, 27, and 41, often brings many cosmetic problems to children and young adults. Considering the disturbing cosmetic problem, the treatment of facial flat wart is always frustrating and often unsuccessful, although there are many treatment modalities. Considering the possible serious side effects of 5-aminolevulinic acid photodynamic therapy (ALA-PDT), we designed step-up therapy of ALA-PDT on different clinical phases of facial flat wart. As a new protocol of ALA-PDT, we found the step-up therapy of ALA-PDT could also receive excellent effects with the lower side effects. Meanwhile, the tolerance of patients to ALA-PDT could improve with subsequent treatment sessions and escalating doses of ALA-PDT.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.